Falciparum Malaria
31
3
3
25
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.2%
1 terminated out of 31 trials
96.2%
+9.6% vs benchmark
26%
8 trials in Phase 3/4
16%
4 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (31)
Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Malaria Molecular Surveillance in Mozambique (Phase 2)
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas
Biological Mechanisms in Afebrile P. Falciparum Malaria
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon
Nitrite Infusion in Children With Malaria
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Tracking Resistance to Artemisinin (TRAC)
Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum
Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Severe Malaria
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria